Genentech’s Ocrevus (ocrelizumab) reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows.
Researchers will present the results at the American Academy of Neurology’s annual meeting in Los Angeles, April 21-27. The presentation will be titled “Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS).”
Biomarkers in cerebrospinal fluid can be an indication of the health of the central nervous system. Not only can they help researchers understand the mechanisms underlying MS but they can also offer insight into therapies’ effectiveness.
Two cerebospinal fluid biomarkers are the neurofilament light chain (NfL) and immune system white blood cells known as lymphocytes.
Researchers are giving the two groups 600-mg intravenous doses of Ocrevus every 24 weeks.
To see how Ocrevus affects cerebrospinal fluid biomarkers, the team inserts a needle into patients’ spinal canal before the treatment and at defined points thereafter — 12, 24, or 52 weeks.
Researchers are using another group of relapsing MS patients as controls. They will have two spinal taps — called lumbar punctures — 12 weeks apart before starting Ocrevus.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?